Cancer Vaccine for Prostate Cancer
(PGV-Prostate Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This proof of concept study is designed to test the safety and tolerability of PGV001-based personalized multi-peptide vaccines in combination with CDX-301 in subjects with a history of aggressive prostate cancer, in the tumor free adjuvant setting.
Who Is on the Research Team?
Ashutosh Tewari, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Sujit S Nair, Ph.D.
Principal Investigator
Icahn School of Medicine at Mount Sinai
Dara Lundon, MD MSc MBA PhD
Principal Investigator
Icahn School of Medicine at Mount Sinai
Are You a Good Fit for This Trial?
This trial is for men over 18 with a history of aggressive prostate cancer who are currently tumor-free. They must have completed all standard treatments, including surgery and chemotherapy, and not be on any immune-suppressing drugs. Participants need good blood counts and organ function, agree to use contraception if necessary, and provide tissue samples for sequencing.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive PGV001-based personalized multi-peptide vaccines in combination with CDX-301
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for radiographic free survival
What Are the Treatments Tested in This Trial?
Interventions
- CDX-301
- PGV-001
- Poly-ICLC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ashutosh Kumar Tewari
Lead Sponsor